Published in Mol Biol Cell on June 27, 2003
Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2006) 2.20
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest (2005) 1.58
A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One (2011) 1.48
Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res (2008) 1.47
The role of SPARC in extracellular matrix assembly. J Cell Commun Signal (2009) 1.43
SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal (2009) 1.41
Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg (2005) 1.38
Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. Mol Biol Cell (2004) 1.29
Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol (2009) 1.27
Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol (2005) 1.22
Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J (2009) 1.20
Revisiting the matricellular concept. Matrix Biol (2014) 1.14
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res (2005) 1.10
Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells. Neoplasia (2011) 1.09
NetSlim: high-confidence curated signaling maps. Database (Oxford) (2011) 1.09
SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity. J Cell Biol (2011) 1.02
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J (2009) 1.02
Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation. PLoS One (2012) 0.98
Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Arch (2005) 0.98
Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res Ther (2010) 0.95
Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis (2007) 0.94
Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev (2011) 0.93
New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res (2012) 0.93
SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One (2010) 0.92
Integrin β4 regulates SPARC protein to promote invasion. J Biol Chem (2012) 0.91
The Function of SPARC as a Mediator of Fibrosis. Open Rheumatol J (2012) 0.89
Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction. World J Biol Chem (2010) 0.88
Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases. J Biomed Res (2012) 0.87
SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT. PLoS One (2012) 0.86
CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder. Virchows Arch (2007) 0.86
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest (2014) 0.86
Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. J Exp Med (2008) 0.86
SPARC expression and prognostic value in non-small cell lung cancer. Chin J Cancer (2012) 0.83
Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice. Gut (2007) 0.82
PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer. PLoS One (2015) 0.82
Attenuation of expression of extracellular matrix genes with siRNAs to Sparc and Ctgf in skin fibroblasts of CTGF transgenic mice. Int J Immunopathol Pharmacol (2011) 0.81
SPARC is expressed in scars of the Tenon's capsule and mediates scarring properties of human Tenon's fibroblasts in vitro. Mol Vis (2011) 0.80
Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial. Chin J Cancer Res (2015) 0.79
Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One (2013) 0.78
The secretome of alginate-encapsulated limbal epithelial stem cells modulates corneal epithelial cell proliferation. PLoS One (2013) 0.78
SPARC Expression Is Selectively Suppressed in Tumor Initiating Urospheres Isolated from As+3- and Cd+2-Transformed Human Urothelial Cells (UROtsa) Stably Transfected with SPARC. PLoS One (2016) 0.78
Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. Am J Physiol Endocrinol Metab (2016) 0.77
Role of taxanes in pancreatic cancer. World J Gastroenterol (2012) 0.77
Differences in gene expression profiles from asbestos-treated SPARC-null and wild-type mouse lungs. Genomics (2009) 0.76
Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments. Thorac Cancer (2017) 0.75
A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth. Sci Rep (2016) 0.75
The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease. Br J Pharmacol (2016) 0.75
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
Role of transforming growth factor beta in human disease. N Engl J Med (2000) 10.17
TGF beta signals through a heteromeric protein kinase receptor complex. Cell (1992) 8.12
Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell (1998) 6.44
Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest (2002) 5.55
Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol (2002) 4.14
SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest (2001) 3.13
Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A (1997) 2.97
Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol (1990) 2.73
The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem (1999) 2.43
The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev (1997) 2.35
Transforming growth factor-beta inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem (1989) 2.29
The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J (1994) 2.22
SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J Cell Biol (1989) 2.10
SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem (1999) 1.93
TGF-beta latency: biological significance and mechanisms of activation. Stem Cells (1997) 1.91
SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem (1998) 1.74
Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. Characterization of chimeric and truncated type I and type II receptors. J Biol Chem (1995) 1.64
Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem (2002) 1.58
TGF-beta: from latent to active. Microbes Infect (1999) 1.55
The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1991) 1.51
Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res (1998) 1.48
SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J Biol Chem (1999) 1.40
Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J Biol Chem (2000) 1.32
SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem (1992) 1.23
Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol (1993) 1.16
SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J Cell Biochem (1998) 1.13
TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol (1994) 1.11
Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell (1999) 1.11
Terms of attachment: SPARC and tumorigenesis. Nat Med (1997) 1.10
Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem (2002) 1.08
Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol (2000) 1.05
SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells. J Biol Chem (1991) 1.02
Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence. J Cell Biochem (1995) 0.99
BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells. Proc Natl Acad Sci U S A (1999) 0.93
Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J Biol Chem (1992) 0.89
Specific interaction of SPARC with endothelial cells is mediated through a carboxyl-terminal sequence containing a calcium-binding EF hand. J Biol Chem (1993) 0.88
Secretion of SPARC by endothelial cells transformed by polyoma middle T oncogene inhibits the growth of normal endothelial cells in vitro. Biochem Cell Biol (1992) 0.87
Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney Int (2000) 0.86
Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. Exp Cell Res (1993) 0.83
Regulation of extracellular matrix proteins by transforming growth factor beta1 in cultured pulmonary endothelial cells. Cell Biol Int (1999) 0.82
Inhibition of G1 phase cyclin dependent kinases by transforming growth factor beta 1. J Cell Biochem (1994) 0.80
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem (2006) 2.47
TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest (2012) 2.44
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res (2007) 2.28
Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2006) 2.20
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest (2009) 2.01
Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol (2009) 1.90
The TGF-beta paradox in human cancer: an update. Future Oncol (2009) 1.79
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res (2006) 1.69
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res (2009) 1.67
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell (2011) 1.66
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis (2008) 1.62
Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem (2002) 1.53
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res (2008) 1.47
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis (2008) 1.45
Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (2011) 1.39
Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2011) 1.38
p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem (2009) 1.37
Role of transforming growth factor-beta in cancer progression. Future Oncol (2006) 1.34
Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. Mol Biol Cell (2004) 1.29
Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells. J Immunol (2008) 1.26
Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol (2004) 1.20
Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J (2009) 1.20
Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res (2004) 1.19
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett (2013) 1.18
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res (2010) 1.16
Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis (2007) 1.15
Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem (2013) 1.15
Repo-man controls a protein phosphatase 1-dependent threshold for DNA damage checkpoint activation. Curr Biol (2010) 1.13
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res (2005) 1.10
NetSlim: high-confidence curated signaling maps. Database (Oxford) (2011) 1.09
Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells. Neoplasia (2011) 1.09
Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvasc Res (2008) 1.08
Fibulin-5 function during tumorigenesis. Future Oncol (2005) 1.05
Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β. Mol Biol Cell (2013) 1.02
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J (2009) 1.02
Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies? Expert Rev Anticancer Ther (2007) 0.98
X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem (2009) 0.98
Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr (2011) 0.97
In vivo dual substrate bioluminescent imaging. J Vis Exp (2011) 0.97
Fibulin-2 and fibulin-5 alterations in tsk mice associated with disorganized hypodermal elastic fibers and skin tethering. J Invest Dermatol (2004) 0.96
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Res (2013) 0.96
Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J (2013) 0.95
Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res (2014) 0.94
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells. Cells Tissues Organs (2010) 0.94
Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells. Breast Cancer Res Treat (2013) 0.93
Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel (2011) 0.91
β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell (2011) 0.90
Fibulin-5 promotes wound healing in vivo. J Am Coll Surg (2004) 0.86
Epithelial-mesenchymal transition in tumor metastasis: a method to the madness. Future Oncol (2009) 0.86
Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor beta signaling. BMC Cell Biol (2004) 0.85
Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer. Transl Oncol (2009) 0.84
Fibromodulin suppresses nuclear factor-kappaB activity by inducing the delayed degradation of IKBA via a JNK-dependent pathway coupled to fibroblast apoptosis. J Biol Chem (2010) 0.79
TGF-beta in cancer and other diseases. Future Oncol (2006) 0.77
Colorectal cancer in the cotton top tamarin (Saguinus oedipus): how do they evade liver metastasis? Dig Dis Sci (2010) 0.76